Most-Downgraded StocksMost-DowngradedNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → Proof that the Musk/Bezos rivalry is about to hit a new level (From InvestorPlace) (Ad) Free ACAD Stock Alerts $15.21 -1.92 (-11.21%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$15.17▼$17.5050-Day Range$15.21▼$24.1352-Week Range$15.17▼$33.99Volume5.28 million shsAverage Volume1.79 million shsMarket Capitalization$2.51 billionP/E RatioN/ADividend YieldN/APrice Target$29.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside93.1% Upside$29.38 Price TargetShort InterestBearish6.76% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 37 Articles This WeekInsider TradingSelling Shares$1.63 M Sold Last QuarterProj. Earnings Growth88.71%From $0.62 to $1.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector159th out of 915 stocksPharmaceutical Preparations Industry56th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.76% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 0.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.9 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 37 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest17 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat Follows11 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 22% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,625,639.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 88.71% in the coming year, from $0.62 to $1.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -40.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -40.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesMay 5, 2024 | insidertrades.comJames Kihara Sells 1,326 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 5, 2024 | insidertrades.comBrendan Teehan Sells 3,477 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 10, 2024 | Crypto 101 Media (Ad)The Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 10, 2024 | insidertrades.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider James Kihara Sells 1,790 SharesMay 10, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 1-Year Low Following Analyst DowngradeMay 9, 2024 | markets.businessinsider.comPositive Buy Rating for ACADIA Pharmaceuticals Amid Solid Market Presence and Underestimated Long-Term OpportunitiesMay 9, 2024 | markets.businessinsider.comMaintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue’s Long-Term Growth ProspectsMay 9, 2024 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call TranscriptMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 9, 2024 | businesswire.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 9, 2024 | markets.businessinsider.comACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy RatingMay 9, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...May 8, 2024 | investorplace.comACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | seekingalpha.comACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | americanbankingnews.comOppenheimer Reiterates "Market Perform" Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)May 7, 2024 | markets.businessinsider.comACADIA Pharmaceuticals is about to announce its earnings — here's what Wall Street expectsMay 5, 2024 | americanbankingnews.comMark C. Schneyer Sells 3,503 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 5, 2024 | americanbankingnews.comStephen Davis Sells 11,427 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMay 4, 2024 | finance.yahoo.comInsider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)May 2, 2024 | stocknews.comBuy Alert: 3 Pharma Stocks Under $20 to Invest in NowMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Sarepta Therapeutics (SRPT) and Acadia Healthcare (ACHC)May 1, 2024 | finance.yahoo.comNewron’s add-on schizophrenia therapy finds success in Phase II/III trialMay 1, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor FitzgeraldApril 30, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)April 29, 2024 | businesswire.comAcadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling ScholarshipApril 28, 2024 | finance.yahoo.comACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years agoApril 24, 2024 | businesswire.comAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024See More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/10/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$29.38 High Stock Price Target$42.00 Low Stock Price Target$19.00 Potential Upside/Downside+93.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E Ratio24.53 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-8.44% Pretax Margin-7.03% Return on Equity-15.67% Return on Assets-9.15% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.28 Sales & Book Value Annual Sales$726.44 million Price / Sales3.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book5.78Miscellaneous Outstanding Shares165,203,000Free Float119,772,000Market Cap$2.51 billion OptionableOptionable Beta0.42 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Executive VP & Head of Research and Development Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMore ExecutivesKey CompetitorsMerusNASDAQ:MRUSMoonLake ImmunotherapeuticsNASDAQ:MLTXBausch Health CompaniesNYSE:BHCMorphoSysNASDAQ:MORTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsTwin Tree Management LPBought 81,700 shares on 5/10/2024Ownership: 0.000%State Board of Administration of Florida Retirement SystemBought 5,300 shares on 5/9/2024Ownership: 0.024%ProShare Advisors LLCBought 3,048 shares on 5/8/2024Ownership: 0.020%Russell Investments Group Ltd.Bought 2,264 shares on 5/8/2024Ownership: 0.013%Headlands Technologies LLCBought 2,601 shares on 5/8/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 15 brokerages have issued 1 year target prices for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $19.00 to $42.00. On average, they expect the company's stock price to reach $29.38 in the next year. This suggests a possible upside of 93.1% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the start of the year. Since then, ACAD shares have decreased by 51.4% and is now trading at $15.21. View the best growth stocks for 2024 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.04 by $0.06. The biopharmaceutical company earned $205.83 million during the quarter, compared to analysts' expectations of $208.31 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 15.67% and a negative net margin of 8.44%. The business's quarterly revenue was up 73.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.27) earnings per share. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Products ETF (BBP).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $966.6 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.40%), Nordea Investment Management AB (0.20%), WCM Investment Management LLC (0.17%), Swiss National Bank (0.13%), Simplex Trading LLC (0.00%) and Privium Fund Management B.V. (0.09%). Insiders that own company stock include Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaProof that the Musk/Bezos rivalry is about to hit a new levelInvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap Profits[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
